Abstract
INTRODUCTION
Whole genome sequencing of the first cancer genome and subsequent efforts to survey the pan-cancer mutational landscape greatly expanded the potential use of cancer variants for research, drug development, and clinical applications (Hudson et al., 2010; Ley et al., 2008; Weinstein et al., 2013) . Clinical application of Next Generation Sequencing (NGS) has enhanced molecular profiling capacity (Kamps et al., 2017) . NGS sequencing methods are now commonly used in personalized clinical cancer care (Chang et al., 2017; Green et al., 2016) .
However, NGS also yields increasing numbers of variants that predominantly are of unknown significance and compounds the challenge of variant interpretation (Good, Ainscough, McMichael, Su, & Griffith, 2014; Kamps et al., 2017) . As clinical analysis of large volumes of patient variant data becomes increasingly difficult, inconsistencies increase both in variant interpretation and reporting between laboratories (Harrison et al., 2017) . This issue is compounded by propagation of these inconsistencies to widely accessed knowledgebases (Hoskinson, Dubuc, & Mason-Suares, 2017; Yorczyk, Robinson, & Ross, 2015) .
This underscores the need for regularized clinical classification and representation, as well as open distribution of standardized somatic cancer variant knowledge (Amendola et al., 2015; Shah & Nathanson, 2017) .
In order to create consistency and transparency in somatic variant interpretation, the Association of Molecular Pathology (AMP) has recently published a set of guidelines for somatic variant interpretation in cancer, which is seeing steady adoption across multiple platforms (Li et al., 2017) . However, currently the field of somatic cancer variant classification is still in development, especially when compared to variant interpretation for germline or Mendelian disorders (Richards et al., 2008; Richards et al., 2015) . Besides the AMP cancer variant interpretation guidelines, there have been several other proposed systems for somatic cancer variant classification, which focus on variant therapeutic value (actionability), broader clinical value, or use more complex bioinformatic approaches to the problem (Hoskinson et al., 2017; Sukhai et al., 2016; Van Allen et al., 2014) .
Minimum variant level data (MVLD; described below and in reference) was developed by The Clinical Genome Resource (ClinGen) Somatic WG (WG) to provide a consensus-based, lightweight, and modular format to transfer somatic variant data of clinical relevance (Ritter et al., 2016) . ClinGen is a global National Institutes of Health (NIH)-funded effort to standardize gene and variant curation, for clinically relevant genetic information, aiding in rapid communication of this information between multiple end users including clinicians, research scientists, and the public. ClinGen works closely with ClinVar, a database of clinically relevant germline and somatic variants, to implement bestpractices in variant curation and presentation (Landrum et al., 2016a Cancer web resource (CIViC-www.civicdb.org) as a curation platform (Griffith et al., 2017) . CIViC is a free, fully open access knowledgebase and curation interface for cancer variants that may potentially impact the clinical evaluation of a cancer patient. The knowledgebase uses a crowdsourcing approach combined with expert curators from organizations such as ClinGen (Expert Panels) and CIViC-trained editors to maintain and expand a resource for clinical interpretation of variants. This addresses a critical need by assisting genome scientists in evaluating the large volume of relevant variant data produced by contemporary tumor NGS analysis (Good et al., 2014) . CIViC is a knowledgebase, which is currently NIH-funded, and provides data with no license restrictions or costs to contribute, use, or view. 
MATERIALS AND METHODS

MVLD brief description
Briefly, MVLD is a metadata structure that guides selection of ontologies and terminologies (Ritter et al., 2016) . MVLD organizes data ele- Evidence field from the Cancer Driver Log (CanDL), the MVLD has been updated and adopted the interpretive tiers from the AMP guidelines (Damodaran et al., 2015; Li et al., 2017) . It is important to note that many somatic variant interpretive schemata could be recorded in the Level of Evidence field (Parsons et al., 2016) . Additionally, at the current time, MVLD is tailored for somatic single nucleotide variants (SNVs) and small insertion and deletion (indel) variants, with the intention to expand for relevant somatic events, such as RNA fusions, gene amplifications, and chromosomal rearrangements.
Curating MVLD formatted variants in CIViC: A workflow method
The CIViC interface is used for variant curation and the creation of variant assertions. The interface enables not only submission of content, but also editing, approval, and discussion regarding changes between curators and editors. Furthermore, it provides tracking and recording of all of these actions, allowing transparency of CIViC curations. In this proposed workflow, the CIViC interface is used to both accept evidence entries from MVLD-formatted and precurated data using general CIViC moderation protocols and to subsequently create variant assertions. An assertion in CIViC is a curation structure built from evidence items (EIDs; structured clinical data extracted from pub- (1) the Somatic WG biocuration team members will curate variants in MVLD format and pull associated PubMed identifiers (PMIDs) into an MVLD record, (2) the MVLD record can then be reassigned to curation team members to pull the PMIDs, review the articles in-depth, extract CIViC EIDs, and enter them into the interface, (3) upon completion of a series of EID entries, a CIViC Somatic Assertion can be created, and (4) the Somatic WG will review and approve a "final" assertion in CIViC.
Harmonizing MVLD and CIViC: A field-to-field analysis
Although the workflow for MVLD-guided ClinGen curation into CIViC (Figure 2 ) does not involve an automated mapping of MVLD-formatted somatic variant data, a field-by-field mapping analysis from MVLD into CIViC was performed to gauge harmonization of the variant representations (Supporting Information Figure S1a -c). In fields where a natural mapping from MVLD to CIViC was not apparent, workarounds were formalized while maintaining the intent of the respective fields from each system. In cases where no workaround of this nature was apparent, the discrepancy was noted and evaluated, and if deemed important, changes to the CIViC variant format were suggested and implemented. Fields in CIViC that were outside the scope of MVLD were also noted, and assessed for their relevance toward variant harmonization between the two representation formats.
Automated CIViC to ClinVar mapping for submission
A formal mapping based on fields drawn from the assertion and variant subsections of CIViC was constructed (Supporting Information In CIViC, such an Assertion clearly links back to the data upon which the Assertion is based, allowing for rapid integration and interpretation in the event of newly published results or the discovery of previously erroneously omitted data.
RESULTS
CIViC development to support
Organizations feature tracks curation progress and ClinVar attributions at a group level
As CIViC has engaged in more collaborations at the organizational level, a feature to group users into organizations was introduced into the interface (Figure 4a ). Every registered CIViC member may belong to one organization, or have no organizational affiliation. An organization page is provided, which features an organization description and list of members (Figure 4b ), along with organizational statistics detailing multiple types of curation activity totals and a list of specific curation actions performed by the organization, as well as a list of all EIDs submitted by organization members (Figure 4c ). An organization for ClinGen Somatic WG members was made in CIViC (Figure 4a-c) , providing proper attribution for this group's efforts throughout the interface and annotating the contributed records for submission to ClinVar using the automated submission process described below. All Somatic Assertions in CIViC will be submitted to ClinVar, and those that have been reviewed by the Somatic WG task teams will be noted as such in the ClinVar submission.
Utilizing ClinGen allele registry in CIViC
ClinGen Allele Registry provides unique and dereferenceable identi- 
Mapping CIViC to ClinVar for variant submission
Using fields made available with the addition of the Assertion feature, we have built a formal procedure for mapping CIViC fields into Figure S2b ). Finally, there are a set of ClinVar submission fields that require procedural generation based on logic that depends on the CIViC submission fields. These fields along with the logic required for generating them are detailed in the Supporting Information Figure S2c . An example of the output of this procedure using a specific assertion (AID5 from Figure 3 ) is also shown in the Supporting Information Figure S3 ).
Harmonizing and relating MVLD to CIViC for streamlined curation
In order to assess harmonization between the MVLD and CIViCformatted somatic variant, we performed a field-by-field mapping of MVLD into CIViC after completion of the CIViC Somatic Assertions update, and analyzed which fields map from MVLD to CIViC in a natural way, which fields require workarounds to map, and which fields did not admit a workaround for mapping. The latter fields in CIViC were analyzed and suggested changes to CIViC were proposed.
Mappable MVLD to CIViC fields
Because MVLD was implemented as a modular, minimal data struc- Figure S1c ), which are discussed below.
Relatable MVLD to CIViC fields
Some fields do not map from MVLD to CIViC in a direct fashion, but admit a relation or adaption to the mapping that does not require 
Nonrelatable MVLD to CIViC fields and implemented CIViC modifications
Other fields in MVLD do not admit a mapping into CIViC, and also did not admit a workflow modification to handle this incongruence. One such set of fields are MVLD's Somatic Interpretive Effect fields that are adopted from Dienstmann, and consist of five levels as follows:
Resistant, Responsive, Not-Responsive, Sensitive, and Reduced Sensitivity (Dienstmann et al., 2014) . In CIViC, the Effect fields are mainly used for the Predictive biomarker class, as opposed to the Diagnostic and Prognostic classes, whereas in MVLD, the Effect field is optional and may be used for prognostic class. In the CIViC EID and Somatic Assertion, data comparable to the MVLD Effect field are 
Comparison of MVLD and CIViC handling of PubMed IDs
Although in an MVLD representation of a somatic variant, the PMID fields are optional to allow for unpublished case data, it is recommended and required in the proposed curation workflow that the 
Required CIViC fields
Curation of diagnostic and prognostic evidence in CIViC requires an evidence direction and Evidence Statement, whereas in MVLD, these This is solved via a guideline to MVLD precuration, which requires curators to assign evidence direction when dealing with diagnostic or prognostic MVLD Biomarker Classes. CIViC also employs a star rating system for submitted evidence, which is a rating of the quality of a unit of evidence submitted to CIViC-in the form of an EID-which is drawn from a publication. ClinGen curators who have read and assessed the evidence being submitted assign these ratings upon submission in the CIViC interface.
Variant curation through somatic expert review and ClinVar submissions 3.3.1 Variant curation standard operating procedure and task teams
The Somatic WG has adopted much of the structure of ClinGen Germline Expert Panels for their curation task teams, and is formalizing the process of Somatic Expert Panels. The Somatic WG is divided into curation task teams focused on cancers and genes, including the fol- A gene-disease search in Mastermind produces a list of variants, and these are prioritized based on the following: (1) overall absence of curated data in CIViC, (2) the number of article hits against the Mastermind search, (3) the number of hits against a PubMed search, and (4) review of variants in pediatric-relevant datasets (Chakravarty et al., 2017; Ma et al., 2018) 
Somatic WG moderation in CIViC
Currently, CIViC editors moderate ClinGen Somatic WG submissions.
Moderation requires a curator with editor-level status to review the literature used to create an EID, after which an editor can directly accept the submission, or if deemed necessary, revise the entry by suggesting revisions. Members of the Somatic WG who specialize in somatic biocuration will receive "editor-level" status to moderate submissions from the ClinGen Somatic WG.
Somatic WG curation and submission to ClinVar
After ClinVar submission of a small test set of somatic assertions, a larger set of 500 submissions is expected to be completed by end of 2018. As part of an ongoing effort, CIViC will submit all assertions to ClinVar on a biannual basis. As we further develop and solidify the submission process and as the rate of assertions in CIViC increases, we may seek to increase the number of submissions. Assertions generated by ClinGen Somatic WG will use the CIViC organization's functionality to be labeled as such for ClinVar submission. ClinVar (Chakravarty et al., 2017; Damodaran et al., 2015; Landrum et al., 2016b; Patterson et al., 2016; Swanton, 2012) . This speaks to the need for coordinated efforts such as that presented here to define and relate central data elements. We hope to extend the interoperability further to additional curation platforms. It is relevant here that the way the community shares clinically identified variants is also rapidly evolving. Many journals, such as Molecular Case Studies, NPJ Genomic Medicine, Human Genome Variation, and JCO Precision Oncology, are beginning to accept cancer genetics case studies as a new publication format. These provide a vehicle and a rapid mechanism to share molecular analysis of patients or cohorts alongside their clinical phenotypic information. These n-of-1 reports are short standardized reports about genomic variation and variability, especially in relation to a disease or drug sensitivity or resistance. However, many journals require submission of variants or sequencing results to public databases in order to promote data sharing. Databases that rely on
DISCUSSION
PMIDs and literature variant curation may not accept relevant cancer cases due to lack of publication evidence. Cancer Genetics will soon implement a new rapid publication model that will highlight interesting cancer cases and associated variants, with the intention that variant data would be submitted to the journal in MVLD format followed by submission and curation in CIViC after PMID assignment. Cancer medicine will greatly benefit from the large scale dissemination of this case-based knowledge to a wide community. In addition, precision oncology could be substantially improved from the biocuration and systematic reviews communities coming together, given the emphasis of the former on timely knowledge dissemination and the latter on systematic assessment of the literature and the risk of bias. For example, curated databases like CIViC could be considered as one of the inputs to systematic reviews while at the same time always including outputs from systematic reviews (Boca, Panagiotou, Rao, McGarvey, & Madhavan, 2018) . The MVLD-CIViC effort outlined here provides a framework to solve these problems, employing MVLD format standardization and CIViC's commitment to ensure no barriers exist for those seeking access to these findings. 
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